Phase III primary objective?

Phase III primary objective?

• A. Demonstrate therapeutic benefit
• B. Describe pharmacokinetics in animal models
• C. Determine dose for Phase I
• D. Assess manufacturing scale-up

Answer: (A)

Phase III trials are designed to confirm that the drug provides a real therapeutic benefit in a large, diverse patient population and to further assess safety under conditions close to real-world use. The primary objective is to demonstrate this efficacy—whether the treatment improves meaningful clinical outcomes compared with placebo or standard care—so the evidence can support approval and labeling. The other options fall outside this central goal: pharmacokinetics in animal models is part of preclinical work, determining the dose for Phase I is about initial safety and dose-finding in early trials, and manufacturing scale-up relates to production readiness (CMC) rather than the trial’s primary efficacy endpoint.

Phase III trials are designed to confirm that the drug provides a real therapeutic benefit in a large, diverse patient population and to further assess safety under conditions close to real-world use. The primary objective is to demonstrate this efficacy—whether the treatment improves meaningful clinical outcomes compared with placebo or standard care—so the evidence can support approval and labeling. The other options fall outside this central goal: pharmacokinetics in animal models is part of preclinical work, determining the dose for Phase I is about initial safety and dose-finding in early trials, and manufacturing scale-up relates to production readiness (CMC) rather than the trial’s primary efficacy endpoint.